Sort
39,280 grants matching “leukemia”
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic Cancer
$394,322Gauri Varadhachary · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
The mechanisms of action of T-lymphocytes in neuropathic pain
$394,317Michael Costigan · Boston Children'S Hospital · R01 · FY2016 · NS
The mechanisms of action of T-lymphocytes in neuropathic pain
$394,317Michael Costigan · Boston Children'S Hospital · R01 · FY2015 · NS
The Contribution ofInfection to Preleukemic Clonal Hematopoiesis
$394,301Katherine Yudeh King · Baylor College Of Medicine · R01 · FY2020 · HL
Fanconi Anemia stem cells allow molecular characterization of acute leukemia
$394,298David W. Clapp · Indiana University Indianapolis · R01 · FY2010 · CA
Biologic Mechanisms and Dosing of Active Music Engagement to Manage Acute Treatment Distress and Improve Health Outcomes in Young Children with Acute Lymphoblastic Leukemia and Parents
$394,286Sheri L Robb · Indiana University Indianapolis · R01 · FY2020 · NR
Good Manufacturing Practice (GMP) and Immune Assessment Core
$394,280Elizabeth J Shpall · University Of Tx Md Anderson Can Ctr · P01 · FY2012 · CA
Regulation of B Cell Development and Function by Zfp521
$394,273James R Hagman · National Jewish Health · R01 · FY2014 · AI
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells
$394,269Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2020 · CA
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells
$394,269Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2023 · CA
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells
$394,269Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2019 · CA
Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD
$394,251Hannah Choe · Ohio State University · R01 · FY2024 · CA
Mechanisms of Liver Cell Injury
$394,250Gregory J. Gores · Mayo Clinic Rochester · R01 · FY2010 · DK
A chicken model to study hepatitis E virus pathogenesis
$394,247Xiang-Jin Meng · Virginia Polytechnic Inst And St Univ · R01 · FY2015 · AI
Ah Receptor Dysregulation Alters Hematopoietic Stem Cells
$394,232Thomas A Gasiewicz · University Of Rochester · R01 · FY2010 · ES
Biologic Mechanisms and Dosing of Active Music Engagement to Manage Acute Treatment Distress and Improve Health Outcomes in Young Children with Acute Lymphoblastic Leukemia and Parents
$394,228Sheri L Robb · Indiana University Indianapolis · R01 · FY2021 · NR
Novel Toxins and Receptors in Mucormycosis Pathogenesis
$394,200Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2019 · AI
Biologic Mechanisms and Dosing of Active Music Engagement to Manage Acute Treatment Distress and Improve Health Outcomes in Young Children with Acute Lymphoblastic Leukemia and Parents
$394,169Sheri L Robb · Indiana University Indianapolis · R01 · FY2023 · NR
Targeting Ceramide Glycosylation in AML
$394,165Myles C Cabot · University Of Virginia · P01 · FY2015 · CA
Ancillary Studies in Clinical Trials - PRIMeR
$394,139Marcelo C. Pasquini · Medical College Of Wisconsin · R01 · FY2011 · HL
Hematopoietic Stem Cell Transplant for GATA2 Deficiency
$394,106Dennis Hickstein · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE
$394,006Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2007 · CA
Epithelial mechanisms of inducible resistance to AML-associated pneumonia
$394,000Scott E. Evans · University Of Tx Md Anderson Can Ctr · R01 · FY2015 · HL
Yes1 as a quiescence regulator in hematopoietic stem cells
$394,000Siddhartha Mukherjee · Columbia University Health Sciences · R01 · FY2015 · HL
Project 6: Clinical Trials Focusing on Microbiota and Novel Cell Therapies
$393,942Sergio A. Giralt · Sloan-Kettering Inst Can Research · P01 · FY2023 · CA